BEIJING (Reuters) - China's Sinovac Biotech said on Monday that a clinical trial in Brazil showed its COVID-19 vaccine was almost 20 percentage points more effective in a small sub-group of patients who received their two doses longer apart.
The protection rate for 1,394 participants who received doses of either CoronaVac or placebo three weeks apart was nearly 70%, a Sinovac spokesman said.
Already a subscriber? Log in
Play, subscribe and stand a chance to win prizes worth over RM39,000! T&C applies.
Cancel anytime. Ad-free. Unlimited access with perks.
